|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
2000 Frontis Plaza Blvd, 250, Winston-Salem, North Carolina 27103, US
|
|
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.
|
ProKidney Corp. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used ProKidney Corp. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact ProKidney Corp. customer service number in your country click here to find.
Janet Cooper-bridge is the CEO of ProKidney Corp.. To contact Janet Cooper-bridge email at [email protected]. Or you may call +1.3369230093 or 3365194441
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.